Inactive Instrument

Yourgene Health

Equities

NIPT

GB00BN31ZD89

Yourgene Health plc Appoints Andrew Leeser as Non-Executive Director

January 25, 2023 at 02:00 am EST

Yourgene Health Plc announcement made on the 21 December 2022 regarding the evolution of the Board, Andrew (Andy) Leeser has been appointed as a Non-executive Director (NED) with immediate effect. Andy is one of the UK's most experienced mid-market corporate transformation specialists. He has been involved with a range of transformation projects and transactions, including refinancings and equity/asset sales across the Automotive, Oil and Gas, Brewing, Retail and Telecommunications sectors.

Recent examples of businesses he has supported include Sepura plc, Sterling Resources (SRUK) and OEG Offshore (Northstar Holding Ltd). He was also part of the team which, in cooperation with HMG, closed the English deep mine coal industry in a controlled manner. Andy is the current Chairman of the Institute for Turnaround (the IFT).

Latest news about Yourgene Health

Yourgene Health Delists Following Novacyt Acquisition	23-09-11	MT
Novacyt: Yourgene officially delisted in London	23-09-11	CF
Novacyt: acquisition of Yourgene Health finalized	23-09-08	CF
Novacyt Completes Acquisition of Yourgene Health	23-09-08	MT
Novacyt completes buy of molecular diagnostics firm Yourgene Health	23-09-08	AN
Novacyt UK Holdings Limited completed the acquisition of Yourgene Health Plc from BGF Investments LP, managed by BGF Investment Management Ltd. and others.	23-09-07	CI
Tintra receives bid approach; NCC trading in line	23-09-07	AN
UK Court OKs Novacyt's Acquisition of Yourgene Health	23-09-07	MT
Yourgene Health Plc Launches MagBench Automated DNA Extraction Instrument and Kit for NIPT Workflows	23-09-05	CI
Yourgene, Pathfinder, Spectral MD and Finncap to be deleted on AIM	23-09-01	AN
Correction: Yourgene Health Shareholders Approve Novacyt UK's Takeover Proposal	23-08-18	MT
Yourgene Health Shareholders Approve Novacyt UK's Takeover Proposal	23-08-18	MT
Novacyt takeover of Yourgene Health closer to completion	23-08-17	AN
Ithaca encouraged by K2; Safestyle profit warning	23-07-27	AN
Yourgene Health inks five-year, Illumina contract extension	23-07-26	AN
Yourgene Health plc Signs Five-Year Contract Extension with Illumina Inc	23-07-26	CI
FTSE 100 Closes Down 0.5% On Back of Astrazeneca's Disappointing Lung-Cancer Data	23-07-03	DJ
Miners and oil majors lead FTSE 100 march	23-07-03	AN
Gilt Yields Rise as BOE Rate Expectations Increase	23-07-03	DJ
Novacyt: shares in demand after Yourgene takeover	23-07-03	CF
AIM WINNERS & LOSERS: Yourgene surges on takeover by Novacyt	23-07-03	AN
Yourgene Health agrees to GBP17 million acquisition offer from Novacyt	23-07-03	AN
Stocks start second half in green amid PMIs	23-07-03	AN
Yourgene Health Surges on GBP17 Million Purchase Deal From Novacyt	23-07-03	MT
London Stocks Seen Opening Marginally Higher as 2nd Half Trading Gets Underway	23-07-03	DJ

Chart Yourgene Health

Duration

Period

More charts

Company Profile

Yourgene Health PLC is an integrated molecular diagnostics company. The Company primarily develops, manufactures, and commercializes molecular diagnostic solutions for reproductive health, precision medicine and infectious diseases. Its segments include Genomic Technologies, which provides in vitro diagnostic products, software and instrumentation, and Genomic Services, which provides services to clinicians, third party clinical service providers and contract research organizations. Its flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and an extension into the precision medicine space with DPYD genotyping. It has a range of deoxyribonucleic (DNA) sample preparation platforms, powered by Ranger Technology, the Yourgene LightBench and Yourgene QS250, ideal for cell-free DNA applications in non-invasive prenatal tests and oncology, including liquid biopsy.

Sector

More about the company